ABSTRACT
SARS-Cov-2 is the novel coronavirus with predominantly inflammatory pathogenesis. The inflammation can be initiated and finally aggravated through a number of interconnected inflammatory pathways such as NF-κB, JAK-STAT, MAPK TLRs, iNOS, COX, etc. In the current chapter, these signaling pathways which instigate inflammation in SARS-Cov-2 are discussed. Moreover, drugs inhibiting these pathways in other inflammatory conditions or diseases are either in clinical use as COVID-19 therapy, or have been proposed as potential future therapeutic interventions in this chapter. These repurposing strategies can halt the COVID-19 symptoms as well as disease progression. This was demonstrated by establishing a link between the regulatory actions of these molecules or drugs in the inflammatory pathway like cytokine release against the COVID-19-related inflammatory havoc. Hence, the chapter will provide profound insights in the inflammatory control pertaining to COVID-19 severity and complications. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023.